Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 23831334)

1.

The use of stimulant medication to improve neurocognitive and learning outcomes in children diagnosed with brain tumours: a systematic review.

Smithson EF, Phillips R, Harvey DW, Morrall MC.

Eur J Cancer. 2013 Sep;49(14):3029-40. doi: 10.1016/j.ejca.2013.05.023. Epub 2013 Jul 4. Review.

PMID:
23831334
2.

Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder.

Tsai CS, Huang YS, Wu CL, Hwang FM, Young KB, Tsai MH, Chu SM.

BMC Psychiatry. 2013 Dec 4;13:330. doi: 10.1186/1471-244X-13-330.

3.

Long-term efficacy of methylphenidate in enhancing attention regulation, social skills, and academic abilities of childhood cancer survivors.

Conklin HM, Reddick WE, Ashford J, Ogg S, Howard SC, Morris EB, Brown R, Bonner M, Christensen R, Wu S, Xiong X, Khan RB.

J Clin Oncol. 2010 Oct 10;28(29):4465-72. doi: 10.1200/JCO.2010.28.4026. Epub 2010 Sep 13. Erratum in: J Clin Oncol. 2010 Dec 20;28(36):5350.

5.

Academic, behavioral, and cognitive effects of OROSĀ® methylphenidate on older children with attention-deficit/hyperactivity disorder.

Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, Starr HL.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):121-31. doi: 10.1089/cap.2010.0047. Epub 2011 Apr 13.

6.

Treatment of attention-deficit/hyperactivity disorder.

Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R.

Evid Rep Technol Assess (Summ). 1999 Nov;(11):i-viii, 1-341.

7.

Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer.

Thompson SJ, Leigh L, Christensen R, Xiong X, Kun LE, Heideman RL, Reddick WE, Gajjar A, Merchant T, Pui CH, Hudson MM, Mulhern RK.

J Clin Oncol. 2001 Mar 15;19(6):1802-8.

PMID:
11251012
8.

Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.

Zwi M, Jones H, Thorgaard C, York A, Dennis JA.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD003018. doi: 10.1002/14651858.CD003018.pub3. Review.

PMID:
22161373
9.

Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.

Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M.

BMC Psychiatry. 2013 Sep 27;13:237. doi: 10.1186/1471-244X-13-237. Review.

11.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
12.

Response to letter that comments on published paper: The use of stimulant medication to improve neurocognitive and learning outcomes in children diagnosed with brain tumours: A systematic review.

Smithson EF, Phillips R, Harvey D, Morrall M.

Eur J Cancer. 2014 May;50(8):1569-70. doi: 10.1016/j.ejca.2014.02.017. Epub 2014 Mar 18. No abstract available.

PMID:
24650580
13.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

14.

Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials.

Senior HE, McKinlay L, Nikles J, Schluter PJ, Carmont SA, Waugh MC, Epps A, Lloyd O, Mitchell GK.

BMC Pediatr. 2013 May 28;13:89. doi: 10.1186/1471-2431-13-89.

15.

Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Loy JH, Merry SN, Hetrick SE, Stasiak K.

Cochrane Database Syst Rev. 2012 Sep 12;9:CD008559. doi: 10.1002/14651858.CD008559.pub2. Review.

PMID:
22972123
16.

Immediate effects of methylphenidate on cognitive attention skills of children with attention-deficit-hyperactivity disorder.

Hood J, Baird G, Rankin PM, Isaacs E.

Dev Med Child Neurol. 2005 Jun;47(6):408-14.

PMID:
15934489
17.

Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder.

Hellwig-Brida S, Daseking M, Keller F, Petermann F, Goldbeck L.

J Child Adolesc Psychopharmacol. 2011 Jun;21(3):245-53. doi: 10.1089/cap.2010.0041.

PMID:
21663427
18.

Executive impairment determines ADHD medication response: implications for academic achievement.

Hale JB, Reddy LA, Semrud-Clikeman M, Hain LA, Whitaker J, Morley J, Lawrence K, Smith A, Jones N.

J Learn Disabil. 2011 Mar-Apr;44(2):196-212. doi: 10.1177/0022219410391191.

PMID:
21383110
19.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
20.

Comment on Smithson et al.'s review of stimulant medication usage to improve neurocognitive and learning outcomes in childhood brain tumour survivors.

Conklin HM, Reddick WE, Khan RB.

Eur J Cancer. 2014 May;50(8):1566-8. doi: 10.1016/j.ejca.2014.01.032. Epub 2014 Mar 24. No abstract available.

PMID:
24675286
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk